Description
Dibicor Pharmacodynamics
Taurine is a natural product of the metabolism of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, a positive effect on the phospholipid composition of cell membranes, normalizes the exchange of calcium and potassium ions in cells. Taurine has been shown to be an inhibitory neurotransmitter, it has an anti-stressor effect, can regulate the release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones, as well as regulate responses to them. Participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; it affects enzymes such as cytochromes responsible for the metabolism of various xenobiotics.
Dibicor improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver disease Dibikor increases blood flow and reduces the severity of cytolysis. It reduces congestion in the small and large circulatory system, decreases intracardiac diastolic pressure and increases myocardial contractility (maximum contraction and relaxation rate, contractility and relaxation indices). The drug moderately reduces blood pressure in patients with arterial hypertension and has almost no effect on the blood pressure in patients with CSF with low blood pressure. Dibicor reduces side effects arising from overdose of cardiac glycosides and “slow” calcium channel blockers; reduces hepatotoxicity of antifungal drugs. Improves performance under heavy physical exertion.
Diabetes mellitus in about 2 weeks after starting the drug Dibicor lowered blood sugar levels. There is also a significant decrease in triglyceride concentration, to a lesser extent – in cholesterol levels, reduction of plasma atherogenicity of lipids. Long-term use of the drug (about 6 months) improved microcirculatory blood flow in the eye.
Indications
– Cardiovascular insufficiency of various etiologies;
– Intoxication caused by cardiac glycosides;
– Diabetes mellitus type 1 and diabetes mellitus type 2
Contraindications
– hypersensitivity to the drug;
– under 18 years of age (efficacy and safety has not been established).
Dosage and administration
- In heart failure Dibicor is taken orally by
250-500 mg (1-2 tablets), 2 times a day for 20 minutes before a meal, the treatment course – 30 days. The dose may be increased to 2-3 g (8-12 tablets) per day or reduced to 125 mg (1/2 tablet) per visit. - If intoxicated with cardiac glycosides, at least 750 mg
(3 tablets) per day. - In diabetes mellitus type 1 – 500 mg (2 tablets) 2 times a day in combination with insulin therapy for 3-6 months.
- In diabetes mellitus type 2 – 500 mg (2 tablets) 2 times a day in monotherapy or in combination with other hypoglycemic agents for oral administration.
- In diabetes mellitus type 2, including with moderate hypercholesterolemia – 500 mg (2 tablets) 2 times a day, the duration of the course – on the doctor’s recommendation.
- As a hepatoprotector – 500 mg (2 tablets) 2 times a day during the course of the antifungal drugs.
